BACKGROUND: Many subjects enrolled in research studies have a limited understanding of the research to which they consented. OBJECTIVE: To develop recommendations to enhance comprehensiveness and understanding of informed consent forms used in critical care clinical trials. DESIGN: Consensus process. RECOMMENDATIONS: We provide recommendations regarding the U.S. federally required basic and additional elements of informed consent as applied to critical care clinical trials. We also identify issues that investigators need to address, if relevant, in the informed consent forms of critical care clinical trials. These include the description, in understandable language, of complex and detailed experimental protocols that are the focus of the clinical trial, disclosure of death as a risk factor if mortality is an outcome variable, and the identification of who can legally serve as the prospective subject's surrogate. We also offer suggestions to enhance subjects' understanding of informed consent forms. CONCLUSIONS: The literature on informed consent forms suggest that shorter informed consent forms written at a lower reading level, when read carefully, might provide better subject understanding. Prospective evaluation is needed to determine whether our recommendations enhance the informed consent process.
BACKGROUND: Many subjects enrolled in research studies have a limited understanding of the research to which they consented. OBJECTIVE: To develop recommendations to enhance comprehensiveness and understanding of informed consent forms used in critical care clinical trials. DESIGN: Consensus process. RECOMMENDATIONS: We provide recommendations regarding the U.S. federally required basic and additional elements of informed consent as applied to critical care clinical trials. We also identify issues that investigators need to address, if relevant, in the informed consent forms of critical care clinical trials. These include the description, in understandable language, of complex and detailed experimental protocols that are the focus of the clinical trial, disclosure of death as a risk factor if mortality is an outcome variable, and the identification of who can legally serve as the prospective subject's surrogate. We also offer suggestions to enhance subjects' understanding of informed consent forms. CONCLUSIONS: The literature on informed consent forms suggest that shorter informed consent forms written at a lower reading level, when read carefully, might provide better subject understanding. Prospective evaluation is needed to determine whether our recommendations enhance the informed consent process.
Authors: Bradley D Freeman; Carie R Kennedy; Dragana Bolcic-Jankovic; Alexander Eastman; Ellen Iverson; Erica Shehane; Aaron Celious; Jennifer Barillas; Brian Clarridge Journal: J Empir Res Hum Res Ethics Date: 2012-02 Impact factor: 1.742
Authors: Bradley D Freeman; Kevin Butler; Dragana Bolcic-Jankovic; Brian R Clarridge; Carie R Kennedy; Jessica LeBlanc; Sara Chandros Hull Journal: Chest Date: 2015-04 Impact factor: 9.410
Authors: Hermann Wrigge; Ulrike Uhlig; Georg Baumgarten; Jan Menzenbach; Jörg Zinserling; Martin Ernst; Daniel Drömann; Armin Welz; Stefan Uhlig; Christian Putensen Journal: Intensive Care Med Date: 2005-08-17 Impact factor: 17.440
Authors: B D Freeman; C R Kennedy; H L Frankel; B Clarridge; D Bolcic-Jankovic; E Iverson; E Shehane; A Celious; B A Zehnbauer; T G Buchman Journal: Pharmacogenomics J Date: 2009-12-08 Impact factor: 3.550
Authors: Ellen Iverson; Aaron Celious; Carie R Kennedy; Erica Shehane; Alexander Eastman; Victoria Warren; Dragana Bolcic-Jankovic; Brian Clarridge; Bradley D Freeman Journal: Chest Date: 2012-12 Impact factor: 9.410
Authors: Susan T Crowley; Glenn M Chertow; Joseph Vitale; Theresa O'Connor; Jane Zhang; Roland M H Schein; Devasmita Choudhury; Kevin Finkel; Anitha Vijayan; Emil Paganini; Paul M Palevsky Journal: Clin J Am Soc Nephrol Date: 2008-04-02 Impact factor: 8.237